Finally, using a screen of clinically relevant compounds, we identify an AHR ligand (“A18”) that can activate AHR and limit TLR4 in human tissue, thus serving as a potential NEC prevention agent when administered in utero. This evidence concerns the gene TLR4 and necrotizing enterocolitis.